Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.

@article{Vinazzer1980ClinicalPS,
  title={Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.},
  author={Helmut Vinazzer and Luciano Fuccella},
  journal={Journal of clinical pharmacology},
  year={1980},
  volume={20 5-6 Pt 1},
  pages={316-25}
}
When given to 12 subjects at single oral doses of 100 and 300 mg, indobufen caused clear-cut, dose-dependent, reversible inhibition of epinephrine- and collagen-induced platelet aggregation. Platelet factor 3 availability and platelet factor 4 release were not affected by the lower dose but were markedly reduced by the 300-mg dose. Bleeding time was slightly influenced by 100 mg, and 300 mg had a more pronounced effect. Indobufen 300 mg was also intravenously injected to five subjects. When… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…